Abstract Library

#1586 Biomarkers for Carcinoid Heart Disease

Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: carcinoid heart disease,

#1585 Incidence and Characteristics of Ileo-colonic Neuroendocrine Tumours Identified in the UK Bowel Cancer Screening Programme

Introduction: Colorectal cancer is the third most common cancer in the UK this had led to development of the bowel cancer screening programmes (BCSPs).There are few epidemiological data on rectal or ileal NETs diagnosed in BCSPs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, O'Donnell K, Brooks C, Srirajaskanthan R, Ramage J,

Keywords: screening,

#1459 Does Faecal Occult Blood Testing Help Identify Ileo-Colonic NETs in the UK Bowel Cancer Screening Programme (BCSP)?

Introduction: There has been an increase in the incidence of ileo-colonic NETs in recent years, partly from endoscopy. There is no published data on the incidence of NETs diagnosed in the UK ‘double’ screen BCSP of initial Faecal Occult Blood stool test (FOBt) and, if abnormal, colonoscopy. The incidence (per 100k) of colorectal cancer (CRC) in FOBt abnormal UK BCSP colonoscopy is 55 times that of the population incidence (10k vs 184).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, O'Donnell K, Brooks C, Srirajaskanthan R, Ramage J,

Keywords: Bowel Cancer Screening, Ileo-colonic, NETs, Rectal,

#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients

Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: Carcinoid Heart Disease, Biomarker,

#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis

Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, Bouvier C, Sissons M, Ramage J, Srirajaskanthan R,

Keywords: IBS, NET, functional diarrhoea,